Becton, Dickinson and Company provided earnings guidance for the fiscal year 2022. On a post-spin basis which reflects the former Diabetes Care business as discontinued operations in both the current and prior-year periods, the company provided the following guidance: The company expects fiscal year 2022 revenues to be in the range of approximately $18.5 billion to $18.7 billion. Revenue guidance for fiscal year 2022 assumes base business currency-neutral revenue growth of 7.25% to 8.25%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
236.6 USD | +0.81% | +1.35% | -2.97% |
May. 06 | Barclays Adjusts Price Target on Becton, Dickinson to $312 From $305, Keeps Overweight Rating | MT |
May. 03 | TD Cowen Adjusts Price Target on Becton, Dickinson and Company to $260 From $271 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.97% | 68.37B | |
-4.02% | 184B | |
-0.75% | 109B | |
+4.48% | 51.56B | |
+9.09% | 44.69B | |
+4.37% | 41.49B | |
+3.12% | 26.75B | |
+4.10% | 26.7B | |
+15.38% | 25.68B | |
-0.94% | 24.8B |
- Stock Market
- Equities
- BDX Stock
- News Becton, Dickinson and Company
- Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2022